Valuation: Alzinova AB

Market Cap 198M 20.75M 18.03M 16.74M 15.44M 29.08M 1.98B 29.61M 77.6M 984M 77.94M 76.23M 3.31B P/E 2026 *
-3.62x
P/E 2027 * -2.57x
Enterprise Value 182M 19.08M 16.57M 15.39M 14.19M 26.73M 1.82B 27.22M 71.33M 905M 71.64M 70.08M 3.04B EV / Sales 2026 *
5.81x
EV / Sales 2027 * -
Free-Float
82.23%
Yield 2026 *
-
Yield 2027 * -
1 day+3.89%
1 week+35.47%
Current month+104.84%
1 month+104.84%
3 months+129.60%
6 months+30.26%
Current year+22.56%
1 week 0.71
Extreme 0.71
1.14
1 month 0.48
Extreme 0.48
1.61
Current year 0.38
Extreme 0.382
1.61
1 year 0.38
Extreme 0.382
2.28
3 years 0.38
Extreme 0.382
4.62
5 years 0.38
Extreme 0.382
8.7
10 years 0.38
Extreme 0.382
44.9
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2024
Chief Operating Officer 54 17/08/2011
Director of Finance/CFO 57 27/03/2024
Director TitleAgeSince
Director/Board Member 61 01/09/2015
Director/Board Member 69 01/01/2018
Director/Board Member - 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
+3.89%+35.47%-39.74%-70.38% 20.38M
-0.80%+5.16%-0.70%+12.87% 48.95B
-3.82%+14.29%+23.71%+5.89% 40.75B
+4.53%+0.22%+411.06%+620.65% 38.46B
-2.01%-1.94%+6.83%+49.58% 36.38B
+5.56%+11.70%+11.64%+51.50% 28.45B
-1.23%-1.59% - - 16.62B
-1.19%-4.64%+31.96%+128.19% 16.33B
-5.79%-1.41%-7.48%-33.21% 13.65B
-0.06%+3.75%+3.81%+9.62% 13.56B
Average +0.05%+9.47%+49.01%+86.08% 25.32B
Weighted average by Cap. -0.03%+7.20%+75.22%+125.89%

Financials

2026 *2027 *
Net sales 31.35M 3.28M 2.85M 2.65M 2.44M 4.6M 313M 4.68M 12.27M 156M 12.33M 12.06M 523M -
Net income -3.2M -335K -291K -270K -249K -470K -31.99M -478K -1.25M -15.89M -1.26M -1.23M -53.43M -50.35M -5.27M -4.58M -4.25M -3.92M -7.39M -503M -7.52M -19.71M -250M -19.8M -19.37M -841M
Net Debt -16M -1.68M -1.46M -1.35M -1.25M -2.35M -160M -2.39M -6.26M -79.44M -6.29M -6.15M -267M -19M -1.99M -1.73M -1.6M -1.48M -2.79M -190M -2.84M -7.44M -94.34M -7.47M -7.31M -317M
Logo Alzinova AB
Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
Employees
7
Date Price Change Volume
31/07/26 SEK 1.016 +3.89% 2,344,913
29/07/26 SEK 0.9780 -5.05% 5,308,647
28/07/26 SEK 1.030 -2.83% 6,080,675
27/07/26 SEK 1.060 +26.19% 8,929,009
24/07/26 SEK 0.8400 +12.00% 3,016,369

Annual profits - Rate of surprise